ArticleFrontiers in medicine2025
Fibromatosis-like metaplastic carcinoma with aggressive metastasis and a TERT promoter mutation: a case report and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Spindle Cell Fibromatosis of the Breast: A Lesson in Malignancy Mimicry.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibromatosis-like metaplastic carcinoma (FLMCa) is a rare, typically indolent subtype of triple-negative breast cancer. This report presents an exceptional case of FLMCa with an aggressive clinical course, challenging the conventional understanding of its low metastatic potential. Methods: A 57-year-old woman presented with a left breast mass. The diagnosis was confirmed via histopathology and immunohistochemistry. Sanger sequencing was used to investigate potential genetic drivers. Results: Pathological examination confirmed FLMCa, characterized by bland spindle cells and a triple-negative immunophenotype. A genetic analysis revealed a C228T mutation in the telomerase reverse transcriptase (TERT) promoter region. Despite multimodal therapy, including surgery, radiotherapy, and multiple lines of chemotherapy, the patient developed lung metastasis at 5 months and bone metastasis at 15 months post-surgery. Conclusion: This case highlights that a subset of FLMCa may exhibit unexpectedly aggressive behavior and resistance to conventional therapy. The presence of a TERT promoter mutation suggests a potential molecular mechanism for this virulence. Our findings advocate for a re-evaluation of risk stratification in FLMCa and underscore the critical need for vigilant follow-up and molecular profiling to guide future targeted therapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.